Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1; the page continues to display a 403 error.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe study record page now displays a 403 Forbidden message instead of the study details, making the record inaccessible to users visiting the page.SummaryDifference19%

- Check25 days agoChange DetectedThe revision tag was updated from v3.6.6 to v3.7.0, indicating a deployment update; no study content changes are introduced.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, indicating a small update to the site's underlying system.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing the previous v3.6.4; this appears to be a software version update with no visible changes to study details or content.SummaryDifference0.1%

- Check75 days agoChange DetectedThe revision tag was updated from v3.6.3 to v3.6.4, indicating a new content release.SummaryDifference0.1%

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.